PacificHealth Laboratories Announces Clinical Results with New Tablet Form of SATIETROL Demonstrates a Significant Reduction in Food Intake

MATAWAN, N.J.--Oct. 16, 2003--
Patented Natural Supplement Helps Control Appetite

PacificHealth Laboratories, Inc. (OTCBB: PHLI), a leading nutrition technology company, announced the first clinical results of a new improved form of its patented appetite control technology, SATIETROL(R), in both beverage and tablet form. The double-blind, placebo-controlled studies showed statistically significant reduction in caloric intake in overweight individuals.

Dr. Robert Portman, President and CEO of PHLI said, "The results from this latest clinical trial, funded by the Company and conducted at a private research firm, are the most significant we've seen with our SATIETROL research program. The study was conducted in 20 overweight subjects who had an average body mass index ("BMI") of 28 (normal BMI is 18-25). We have focused our efforts on improving the efficacy of SATIETROL for weight loss while developing more convenient and consumer-friendly forms for this patented technology. We have now confirmed in three double-blind trials that this new form of SATIETROL reduces caloric intake from 10-14%."

Dr. Portman continued, "These studies have also indicated that this improved form of SATIETROL is effective in reducing food consumption in two new delivery forms: chewable tablets and when added to low-calorie ice tea. This finding sets the stage for a totally new class of low-calorie functional beverages that naturally reduce appetite and hunger, both compelling consumer advantages with widespread health implications."

Dr. Portman concluded, "We believe that these new forms of SATIETROL represent valuable tools for the 60 million Americans who are deemed overweight by government statistics. SATIETROL is the first product that works by stimulating the body's own satiety peptide, cholecystokinin (CCK). Prescription drugs that work by stimulating satiety peptides may be the wave of the future for weight control, but they may not be available for 7-10 years. SATIETROL is the first over-the-counter product in this category and is safe, effective, and all natural. We are in the process of fielding additional clinical studies including a 12-week double blind weight loss study that will be conducted at a major university. Depending on the results of these trials, the improved form of SATIETROL in a chewable tablet could be marketed within 12-18 months. We also intend to explore the possibility of licensing the SATIETROL technology to one or more beverage manufacturers."

About PacificHealth Laboratories:

PacificHealth Laboratories, Inc. was founded in 1995 to develop and commercialize functionally unique nutritional products for sports performance, weight loss, and control of Type 2 diabetes. To learn more about PacificHealth Laboratories visit

This news release contains forward-looking statements. These statements can be identified by introductory words such as "expects", "plans", "will", "estimates", "forecasts", "projects" or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.